Advertisement
Letter to the Editor| Volume 78, P157-158, August 2020

The Impact Of Diabetes Mellitus And Microvascular Complications On Heart Failure Biomarkers

Published:April 15, 2020DOI:https://doi.org/10.1016/j.ejim.2020.04.025
The Impact Of Diabetes Mellitus And Microvascular Complications On Heart Failure Biomarkers
Previous ArticleComparative prediction of long-term mortality by the CHA2DS2-VASc score and cardiac troponin I levels in patients with atrial fibrillation at the emergency department
Next ArticleManagement and outcomes of post-acute COVID-19 patients in Northern Italy

      Highlights

      • •
        HF-biomarkers used in the general population are also suitable in patients with DM
      • •
        sST2 levels are significantly correlated with NT-proBNP and hypocholesterolemia
      • •
        Gal-3 sees the highest levels in subjects with DM and microvascular complications
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Shah A.D.
        • Langenberg C.
        • Rapsomaniki E.
        • Denaxas S.
        • Pujades-Rodriguez M.
        • Gale C.P.
        • et al.
        Type 2 Diabetes And Incidence Of Cardiovascular Diseases: A Cohort Study In 1•9 Million People.
        Lancet Diabetes Endocrinol. 2015; 3: 105-113
        View in Article
        • Chow S.L.
        • Maisel A.S.
        • Anand I.
        • Bozkurt B.
        • de Boer R.A.
        • Felker G.M.
        • et al.
        Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
        Circulation. 2017; 135: e1054-e1091
        View in Article
        • Sandesara P.B.
        • O'Neal W.T.
        • Kelli H.M.
        • Samman-Tahhan A.
        • Hammadah M.
        • Quyyumi A.A.
        • Sperling L.S.
        The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.
        Diabetes Care. 2018; 41: 150-155
        View in Article
        • Kozakova M.
        • Palombo C.
        Diabetes Mellitus, Arterial Wall, and Cardiovascular Risk Assessment.
        Int J Environ Res Public Health. 2016; 13: 201
        View in Article
        • Domanski M.
        • Krause-Steinrauf H.
        • Deedwania P.
        • Follmann D.
        • Ghali J.K.
        • Gilbert E.
        • et al.
        The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
        J Am Coll Cardiol. 2003; 42: 914-922
        View in Article
        • Macdonald M.R.
        • Petrie M.C.
        • Varyani F.
        • Östergren J.
        • Michelson E.L.
        • Young J.B.
        • et al.
        Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
        Eur Heart J. 2008; 29: 1377-1385
        View in Article
        • Ohkuma T.
        • Jun M.
        • Woodward M.
        • Zoungas S.
        • Cooper M.E.
        • Grobbee D.E.
        • et al.
        Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial.
        Diabetes Care. 2017; 40: 1203-1209
        View in Article
        • Sitar Taut A.V.
        • Pop D.
        • Zdrenghea D.T.
        NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes.
        J Diabetes Complications. 2015; 29: 1119-1123
        View in Article
        • Atalar M.N.
        • Abuşoğlu S.
        • Ünlü A.
        • Tok O.
        • İpekçi S.H.
        • Baldane S.
        • Kebapcilar L.
        Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes.
        Life Sci. 2019; 231116577
        View in Article
        • Lin Y.H.
        • Zhang R.C.
        • Hou L.B.
        • Wang K.J.
        • Ye Z.N.
        • Huang T.
        • et al.
        Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes.
        Diabetes Res Clin Pract. 2016; 118: 140-145
        View in Article

      Article info

      Publication history

      Published online: April 15, 2020
      Accepted: April 8, 2020
      Received in revised form: April 6, 2020
      Received: February 2, 2020

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2020.04.025

      Copyright

      © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX